Tranamic Use In Pregnancy & Lactation

Pregnancy: Teratogenic Effects: Pregnancy Category C. Reproduction studies have been performed in rats, rabbits and dogs. Rats given up to 10 times the human dose showed decreased fertility, delay in parturition and a decreased rate of survival to weaning. Rabbits at 2.5 times the human dose showed an increase in the number of resorptions. There were no fetal anomalies observed in these studies now in dogs at up to 10 times the human dose.
However, animal reproduction studies are not always predictive of human response. There are no adequate and well-controlled studies in pregnant women. Mefenamic acid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nonteratogenic Effects: Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.
Labor and Delivery: In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition and decreased pup survival occurred. The effects of mefenamic acid on labor and delivery in pregnant women are unknown.
Nursing Mothers: Trace amounts of mefenamic acid may be present in breast milk and transmitted to the nursing infant. Because of the potential for serious adverse reactions in nursing infants from mefenamic acid a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.